Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831369) titled 'VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma' on Sept. 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Inova Health Care Services
Condition:
Glioblastoma
Astrocytoma, IDH-Mutant, Grade 4
Intervention:
Drug: Valproic Acid (VPA)
Drug: Irinotecan
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 4, 2026
Target Sample Size: 52
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials...